

# Megan K Young

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7775200/publications.pdf>

Version: 2024-02-01

26  
papers

1,114  
citations

1039406

9  
h-index

752256

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1060  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long covidâ€™ mechanisms, risk factors, and management. <i>BMJ, The</i> , 2021, 374, n1648.	3.0	946
2	Identification of focus areas for Australian Bat Lyssavirus potential exposure prevention in the Metro North Hospital and Health Service region. <i>Zoonoses and Public Health</i> , 2020, 67, 732-741.	0.9	1
3	Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 641-644.	1.5	0
4	Clinical experience of intramuscular immunoglobulin for measles prophylaxis in children: Is it practical?. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 364-366.	0.4	0
5	Singing for people with Parkinson's disease. <i>The Cochrane Library</i> , 2019, , .	1.5	1
6	The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2060-2065.	1.4	13
7	Potential exposure to Australian bat lyssavirus is unlikely to prevent future bat handling among adults in South East Queensland. <i>Zoonoses and Public Health</i> , 2018, 65, e237-e242.	0.9	4
8	Immunisation Promotion in the Hospital Outpatient Department. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 1280-1281.	0.4	0
9	The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 663-669.	1.5	4
10	Rubella antibodies in Australian immunoglobulin products. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1952-1955.	1.4	4
11	Do Australian immunoglobulin products meet international measles antibody titer standards?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 607-612.	1.4	11
12	Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. <i>The Cochrane Library</i> , 2015, 2015, CD010586.	1.5	16
13	Informing the public health management of typhoid and paratyphoid: the Australian context. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 577-581.	0.8	1
14	Hepatitis A virus antibodies in Australian blood donors: Implications for immunoglobulin sufficiency. <i>Vaccine</i> , 2015, 33, 5135-5139.	1.7	4
15	Preventing Australian Bat Lyssavirus: Community Knowledge and Risk Perception of Bats in South East Queensland. <i>Vector-Borne and Zoonotic Diseases</i> , 2014, 14, 284-290.	0.6	13
16	Post-exposure passive immunisation for preventing measles. <i>The Cochrane Library</i> , 2014, , CD010056.	1.5	34
17	Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinsonâ€™s disease. <i>Quality of Life Research</i> , 2013, 22, 1065-1072.	1.5	22
18	Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1885-1893.	1.4	11

#	ARTICLE	IF	CITATIONS
19	The time has come for an Australian Centre for Disease Control. Australian Health Review, 2013, 37, 300.	0.5	1
20	Potential exposure to Australian bat lyssavirus in south east Queensland: what has changed in 12 years?. Communicable Diseases Intelligence Quarterly Report, 2010, 34, 334-8.	0.6	8
21	Fluoride content of powdered infant formula meets Australian Food Safety Standards. Australian and New Zealand Journal of Public Health, 2009, 33, 573-576.	0.8	9
22	Health partnerships: perspectives of medical practitioners in general practice, health systems and hospital settings. Australian Journal of Primary Health, 2009, 15, 319.	0.4	4
23	An outbreak of Clostridium perfringens and the enforcement of food safety standards. Communicable Diseases Intelligence Quarterly Report, 2008, 32, 462-5.	0.6	0
24	Authors stand by recommendation on water heating. Australian and New Zealand Journal of Public Health, 2006, 30, 289-290.	0.8	0
25	Trends in potential exposure to Australian bat lyssavirus in South East Queensland, 1996 to 2003. Communicable Diseases Intelligence Quarterly Report, 2004, 28, 258-60.	0.6	7
26	The use of normal human immunoglobulin (NHIG) for public health purposes in Queensland 2004-2014 and Australia 2014-2016. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	0